BTOG WCLC 2026 Highlights Update with Tom Newsom-Davis and Riyaz Shah

What were the key lung cancer studies from the 2026 World Conference on Lung Cancer – and what could they mean for clinical practice in the UK? In this BTOG webcast and podcast, Dr Tom Newsom-Davis, Chair of BTOG and Consultant Thoracic Medical Oncologist at Chelsea and Westminster Hospital, is joined by Riyaz Shah, Consultant Medical Oncologist at Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, and BTOG Steering Committee Vice-Chair. Together, they discuss six highlights from WCLC 2026, including new data in HER2-mutated and EGFR exon 20 insertion-positive lung cancer; emerging treatments for ROS1-positive disease; the rapidly changing treatment landscape in small cell lung cancer; whether prophylactic cranial irradiation (PCI) still has a role in the era of MRI surveillance; and the eight-year survival results from ADAURA. Throughout the discussion, Tom and Riyaz consider not only the headline results, but also toxicity, patient choice, access and reimbursement, and what the findings could mean for UK clinical practice.